Evolva Holding SA of Switzerland, which specialises in synthetic biology, has announced plans to acquire the US venture-capital backed Abunda Nutrition Inc in an all-share transaction valued at approximately CHF 40.5 million (€31.3 million).
The AstraZeneca Plc unit, MedImmune, has entered into a three-year collaboration with the technology transfer arm of France’s National Institute of Health and Medical Research (Inserm) to research disease and potential drug candidates.
MDxHealth SA, the Belgian molecular diagnostics company, is intending to raise at least €6 million with a private placement of its shares managed jointly by Kempen & Co and Nomura Code Securities.
Qiagen NV, the Netherlands-based diagnostic group, has made a bid equivalent to $355 million to acquire Cellestis Ltd of Australia and its ‘pre-molecular’ technology for detecting diseases early.
Algeta ASA and Genzyme Corp (Sanofi-Aventis) have announced plans to jointly explore the use of the Norwegian company’s radiopharmaceutical platform to enhance the ability of a Genzyme monoclonal antibody to target and kill cancer.
Acacia Pharma Ltd, which specialises in drugs for cancer supportive care, has raised $10 million in a Series A financing round supported by the new investor, Lundbeckfond Ventures. Gilde Healthcare also participated in the round.
Newron Pharmaceuticals SpA has reached a licensing agreement with Merck Serono to investigate the potential of two Merck clinical-stage compounds for disorders of the central nervous system. Financial terms weren’t disclosed.
A Phase-3 study of motesanib, a small molecule antagonist of vascular endothelial growth factor (VEGF) receptors, failed to meet its primary endpoint of improving the overall survival for patients with advanced, non-squamous, non-small cell lung cancer (NSCLC), the sponsor said.
Anergis SA, a privately held Swiss company developing immunotherapy for allergies, has received an endorsement of its technology with a CHF18 million (€14 million) Series “A” venture financing.
The US Food and Drug Administration has approved a new monoclonal antibody, Yervoy (ipilimumab), to treat patients with late-stage melanoma, the most dangerous type of skin cancer. The antibody is manufactured by Bristol-Myers Squibb Inc.